The Symbiotec Pharmalab IPO has opened for subscription today, August 24, 2026.
The pharmaceutical company is looking to raise Rs 1,757 crore through the public issue.
The IPO will remain open until August 27.
Before applying, investors should know the issue size, price band, minimum investment, allotment date and how the company plans to use the money.
Here are 10 important things to know.
Symbiotec Pharmalab IPO Size
The company plans to raise Rs 1,757 crore through the IPO.
The issue includes a fresh issue of Rs 150 crore and an offer for sale (OFS) worth Rs 1,607 crore.
What Is the IPO Price Band?
Symbiotec Pharmalab has fixed the price band at Rs 938 to Rs 988 per share.
Investors can place their bids within this price range during the subscription period.
How Much Money Is Needed to Apply?
The IPO has a lot size of 15 shares.
At the upper price of Rs 988 per share, investors will need at least Rs 14,820 to buy one lot.
When Can You Subscribe?
The IPO opened on August 24, 2026, and will close on August 27, 2026.
Investors need to submit their bids within this four-day subscription window.
When Will Allotment and Listing Take Place?
The IPO allotment is expected to be finalised on August 28, 2026.
The shares are proposed to be listed on both the NSE and BSE.
The tentative listing date is September 1, 2026.
How Is the IPO Reserved for Different Investors?
The company has divided the issue among different categories of investors.
Up to 50% of the net offer is reserved for Qualified Institutional Buyers (QIBs).
At least 35% is reserved for retail investors, while at least 15% is reserved for non-institutional investors (NIIs).
Where Will the IPO Money Be Used?
Symbiotec Pharmalab plans to use most of the money raised through the fresh issue to prepay or repay certain outstanding borrowings.
The remaining funds will be used for general corporate purposes.
Most of the IPO Is an Offer for Sale
This is an important point investors should understand.
Out of the total Rs 1,757 crore IPO, as much as Rs 1,607 crore is an Offer for Sale.
Only Rs 150 crore will come into the company through the fresh issue.
The money raised through the OFS will go to the existing selling shareholders rather than the company.
What Does Symbiotec Pharmalab Do?
Founded in 2002, Symbiotec Pharmalab operates in the pharmaceutical and biotechnology sector.
The company develops and manufactures active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products.
It serves both Indian and international markets, including regulated and emerging markets.
The company has approvals from regulatory bodies and organisations including the US FDA, EU-GMP and South Korea’s Ministry of Food and Drug Safety.
What Is the Company’s Manufacturing Capacity?
As of June 30, 2025, Symbiotec Pharmalab operated two industrial-scale API manufacturing facilities.
Together, these facilities had a maximum chemical synthesis capacity of 584.67 metric tonnes (MT).
The company also had a fermentation capacity of 300 kilolitres.
Symbiotec Pharmalab IPO: Important Dates and Details
| Particulars | Details |
|---|---|
| IPO opens | August 24, 2026 |
| IPO closes | August 27, 2026 |
| IPO size | Rs 1,757 crore |
| Price band | Rs 938–Rs 988 per share |
| Lot size | 15 shares |
| Minimum investment | Rs 14,820 |
| Fresh issue | Rs 150 crore |
| Offer for Sale (OFS) | Rs 1,607 crore |
| Allotment date | August 28, 2026 |
| Tentative listing date | September 1, 2026 |
| Listing exchanges | NSE and BSE |
What Should Investors Keep in Mind?
The Symbiotec Pharmalab IPO gives investors an opportunity to invest in a pharmaceutical company with domestic and international operations.
However, investors should look beyond the IPO’s size and brand name. The fact that a large portion of the issue is an OFS is also important to consider.
Before subscribing, investors should review the company’s financial performance, valuation, business risks and IPO documents carefully.
